Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma.

Autor:	Jansen CS; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States.; Winship Cancer Institute of Emory University, Atlanta, GA, United States.; Emory University School of Medicine, Atlanta, GA, United States., Choi Y; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States.; Winship Cancer Institute of Emory University, Atlanta, GA, United States., Evans ST; Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States., Greenwald R; Department of Urology, Emory University School of Medicine, Atlanta, GA, United States., Behnke JA; Emory University School of Medicine, Atlanta, GA, United States., Hartman C; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States.; Winship Cancer Institute of Emory University, Atlanta, GA, United States., Kissick H; Winship Cancer Institute of Emory University, Atlanta, GA, United States.; Department of Urology, Emory University School of Medicine, Atlanta, GA, United States., Harik LR; Winship Cancer Institute of Emory University, Atlanta, GA, United States.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States., Bilen MA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States.; Winship Cancer Institute of Emory University, Atlanta, GA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Oct 04; Vol. 13, pp. 1271255. Date of Electronic Publication: 2023 Oct 04 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1271255
Abstrakt:	Extrarenal clear cell renal cell carcinoma (eccRCC) is a rare type of RCC that arises in areas other than the kidney. Given its rarity, consensus guidelines for optimal treatment of eccRCC have not been established, and the literature is lacking any reports of patient response to systemic therapy and any reports of administration of immunotherapy to patients with ecRCC. Here, we present the case of a patient in their 60s with eccRCC arising in the spleen. The patient underwent splenic resection and then received systemic therapy, due to disease recurrence, with a combination of immunotherapy (IO) and tyrosine kinase inhibitor targeted therapy (VEGF-TKI). The patient had an excellent and durable response to this therapeutic regimen with minimal adverse effects, completing 2 years of therapy of nivolumab and cabozantinib. At the time of this report, the disease remains stable. This case demonstrates that combination therapy with IO+VEGF-TKI represents a reasonable and well-tolerated treatment option with activity in eccRCC and reveals interesting correlative data, including nests of stem-like CD8+T-cell infiltration in tumor tissue, which provide important biological context to this patient's exceptional therapeutic response. Competing Interests: MB has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi, and his institution has received grants from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed outside of the current study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Jansen, Choi, Evans, Greenwald, Behnke, Hartman, Kissick, Harik and Bilen.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu